Inspra, as an aldosterone receptor antagonist, is mainly metabolized by the CYP3A enzyme system, and its combination with CYP3A inhibitors may lead to abnormally high blood drug concentrations. The following provides a detailed analysis of the types and specific drugs of CYP3A inhibitors that need to be avoided, as well as an explanation of their interaction mechanisms and clinical management recommendations.

1. Prohibited combination of potent CYP3A inhibitors

(1) Triazole antifungal drugs: Ketoconazole and itraconazole can increase the AUC of eplerenone by more than 5 times, and their combination is absolutely contraindicated.

(2) HIV protease inhibitors, such as ritonavir and nelfinavir, significantly increase the concentration of eplerenone by irreversibly inhibiting CYP3A.

(3) Macrolide antibiotics such as clarithromycin and gibberellin should be permanently avoided.

2. Moderate acting CYP3A inhibitors that require caution

(1) Calcium channel blocker: When combining diltiazem and verapamil, the dose of eplerenone should be adjusted to start at 25mg/day.

(2) Fluoroquinolones: Ciprofloxacin may moderately inhibit CYP3A. It is recommended to monitor blood pressure and blood potassium during combination use.

(3) Grapefruit products: containing furan coumarin components, which may increase the exposure to eplerenone by 2-3 times, should be avoided from consumption.

3. Other high-risk interacting drugs

(1) Angiotensin receptor antagonists (ARBs): When used in combination with losartan and other drugs, they synergistically increase the risk of hyperkalemia and require enhanced monitoring.

(2) Potassium sparing diuretics: spironolactone and paracetamol should not be used in combination, otherwise it may cause fatal hyperkalemia.

(3) Non steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may weaken their blood pressure lowering effect and worsen kidney function damage, especially for elderly patients who need to be vigilant.

4. Key points of clinical management

(1) Pre medication screening: Before prescribing eplerenone, a comprehensive evaluation of the patient's current medication history is required, with a focus on screening CYP3A inhibitors.

(2) Alternative: When antifungal treatment is necessary, fluconazole (a weak CYP3A inhibitor) can be used instead of itraconazole.

(3) Emergency treatment: If hypotension or hyperkalemia occurs after accidental combination therapy, the medication should be stopped immediately and intravenous fluid should be administered to correct it.